Promising Breakthrough in Psoriasis Treatment: Johnson & Johnson’s JNJ-2113 Achieves Stellar Results
SPRING HOUSE, PA — In a remarkable breakthrough for the healthcare industry, Johnson & Johnson’s investigational targeted oral peptide, JNJ-2113, has displayed positive results in a Phase 2b study for …
Promising Breakthrough in Psoriasis Treatment: Johnson & Johnson’s JNJ-2113 Achieves Stellar Results Read More